Search Login Register

ximelagatran (Exanta) Summary

Description: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this

Also Known As: Exanta; H 376 95; H 376-95; glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester Show All >>

Networked: 233 relevant articles (40 outcomes, 121 trials/studies) for this Bio-Agent

Key Diseases for which ximelagatran is Relevant

  1. Stroke (Strokes) : 15 outcomes 54 studies in 90 results
  2. Atrial Fibrillation : 14 outcomes 54 studies in 103 results
  3. Venous Thromboembolism : 13 outcomes 39 studies in 85 results
  4. Hemorrhage : 7 outcomes 20 studies in 69 results
  5. Venous Thrombosis (Deep-Vein Thrombosis) : 6 outcomes 16 studies in 35 results
Show All >>

Drugs Related to ximelagatran

  1. Thrombin
  2. Warfarin (Coumadin)
  3. Enoxaparin (Lovenox)
  4. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
  5. melagatran
  6. Anticoagulants
  7. Aspirin (Acetylsalicylic Acid)
  8. Vitamin K
  9. idraparinux
  10. Factor Xa (Coagulation Factor Xa)
Show All >>

Therapies Related to ximelagatran

  1. Knee Replacement Arthroplasty (Total Knee Replacement)
  2. Arthroplasty
  3. Hip Replacement Arthroplasty (Total Hip Replacement)
  4. Oral Administration
  5. Orthopedic Procedures
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.